ArticleFrontiers in immunology2023
A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease.
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Pooled it
- Gut microbiota and metabolic characteristics in PWHIV with metabolic dysfunction-associated steatotic liver disease (MASLD).Virulence · 2027Article
- Intestinal Microbiome, Fecal Fermentation Profile, and Health Indices in HIV-Positive Men Versus Normal Controls Without HIV.Nutrients · 2026Article
- Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated alcohol-related liver disease in human immunodeficiency virus.World journal of virology · 2026Review
- Non-Hispanic Black Persons With HIV Have a Lower Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease and Clinically Significant Fibrosis Compared to Non-Hispanic White and Hispanic Individuals.Open forum infectious diseases · 2026Article
- Divergent Successional Patterns ofMicroorganisms · 2026Article
- Intersections of vitamin D deficiency, HIV and chronic liver diseases.HIV medicine · 2026Review
- Gut microbiomes-host immune response and organ dysfunction across the gut-lung, gut-brain, and gut-liver axes.Frontiers in cellular and infection microbiology · 2026Review
- Metabolic dysfunction-associated steatotic liver disease in people living with HIV: mechanisms, diagnosis, and management.Frontiers in immunology · 2026Review
- The Effect of Short-Term and High-Intensity Functional Circuit Training on Plasma Lipidome Profiles of People Living with and Without HIV.Metabolites · 2025Article
- Pathogenesis of metabolic dysfunction-associated steatotic liver disease and donor liver damage.iLIVER · 2025Review
- Metabolomics for searching non-invasive biomarkers of metabolic dysfunction-associated steatotic liver disease in youth with vertical HIV.Communications medicine · 2025Article
- From Steatosis to Immunosenescence: The Impact of Metabolic Dysfunction on Immune Aging in HIV and Non-HIV Populations.Biomedicines · 2025Review
- Distinct Gut Microbiota Signatures Are Associated with Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease in People with HIV.International journal of molecular sciences · 2025Article
- Association between gut microbiota in HIV-infected patients and immune reconstitution following antiretroviral therapy (ART).BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), has emerged as an increasingly recognized problem among people living with HIV (PLWH). The gut-liver axis is considered to be strongly implicated in the pathogenesis of MASLD. We aimed to characterize the gut microbiota composition in PLWH and MASLD and compare it with that of two control groups: PLWH without MASLD and individuals with MASLD without HIV infection. Methods: We collected clinical data and stool samples from participants. Bacterial 16S rRNA genes were amplified, sequenced, and clustered into operational taxonomic unit. Alpha diversity was studied by Shannon and Simpson indexes. To study how different the gut microbiota composition is between the different groups, beta diversity estimation was evaluated by principal coordinate analysis (PCoA) using Bray-Curtis dissimilarity. To further analyze differences in microbiome composition we performed a linear discriminant analysis (LDA) effect size (LEfSe). Results: We included 30 HIV Conclusions: We found a microbiome signature linked to MASLD, which had a greater influence on the overall structure of the gut microbiota than HIV status alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.